Groups | A | B | C | D | E | F | ||
---|---|---|---|---|---|---|---|---|
Virus tested | PRVΔTK&gE-AH02 | Bartha K61 | / | / | ||||
Dosage (TCID50) | 103 | 104 | 105 | 105 | / | / | ||
Inoculation route | Intramuscularly | |||||||
ELISA antibodies against PRV gB or gE | B.V. | gB+ | 0a/4b | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
gE+ | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
7d P.V. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 0/4 | 0/4 | |
gE+ | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
14 d P.C. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 0/4 | 0/4 | |
gE+ | 4/4 | 4/4 | 4/4 | 4/4 | 1/1 | 0/4 | ||
Clinical signs P.V. | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
Fever frequency (≥40.5 °C) P.V. | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
Virus shedding P.V. | 0/4 | 0/4 | 0/4 | 0/4 | / | / | ||
Fever frequency (≥40.5 °C) P.C. | 0/4 | 0/4 | 0/4 | 4/4 | 4/4 | 0/4 | ||
Clinical signs P.C. | Morbidity | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 | 0/4 | |
Duration (days) | / | / | / | / | 4~ 9 | / | ||
Mortality | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 0/4 | ||
Virus shedding P.C. | Frequency | 0/4 | 0/4 | 0/4 | 4/4 | 4/4 | 0/4 | |
Duration (days) | / | / | / | 3~ 5 | 2~ 9 | / | ||
Lung lesions | 0/4 | 0/4 | 0/4 | 2/4 | 4/4 | 0/4 |